Physician profile
Cherese M Laporta
NPI 1437206943
$11,127.55
in general payments reported to CMS, 2019-2025
52 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,314 · 2020: $1,829 · 2021: $1,886 · 2022: $1,236 · 2023: $1,520 · 2024: $1,288 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,863.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,198.79 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $945.81 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $866.33 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $839.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $820.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $787.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $723.05 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $605.50 | 2019-2025 | |
| Allergan, INC. | $492.73 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $485.94 | 2019-2025 | Glassia |
| Merck Sharp & Dohme LLC | $436.59 | 2019-2021 | |
| Alkermes, INC. | $266.89 | 2019-2023 | Vivitrol |
| Indivior INC. | $238.60 | 2019-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $213.60 | 2019-2022 | |
| Amarin Pharma, INC. | $190.42 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherese Laporta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.